Agos­ti­ni Ltd has un­der­gone a trans­for­ma­tion since 2020, more than dou­bling the scale of its op­er­a­tions through a com­bi­na­tion of strate­gic ac­qui­si­tions and steady or­gan­ic growth across its phar­ma­ceu­ti­cal, health­care, man­u­fac­tur­ing and dis­tri­b­u­tion busi­ness­es.

In 2020, Agos­ti­ni was large­ly a lo­cal en­ter­prise, op­er­at­ing in six mar­kets with rev­enues of $3.43 bil­lion and as­sets to­talling $2.71 bil­lion. Fast for­ward to to­day and the com­pa­ny has sig­nif­i­cant­ly widened its re­gion­al foot­print, now op­er­at­ing in 10 mar­kets, gen­er­at­ing $5.44 bil­lion in rev­enue and hold­ing $4.83 bil­lion in as­sets. The group's as­set base should be fur­ther boost­ed by two on­go­ing ac­qui­si­tions.

The Chris­t­ian Mout­tet–chaired group marked a ma­jor mile­stone in Ju­ly when it cel­e­brat­ed its 100th an­niver­sary. Last year, as part of that cen­ten­ni­al evo­lu­tion, the com­pa­ny in­tro­duced two core brands aimed at uni­fy­ing its iden­ti­ty across the re­gion. Aven­ta now hous­es Agos­ti­ni’s phar­ma­ceu­ti­cal and health­care busi­ness­es, while Aca­do rep­re­sents its man­u­fac­tur­ing and dis­tri­b­u­tion op­er­a­tions. The group al­so stream­lined its cor­po­rate iden­ti­ty last year, of­fi­cial­ly re­brand­ing from Agos­ti­ni’s to Agos­ti­ni in Feb­ru­ary.